IL243833A0 - Therapeutically active compounds and methods of use - Google Patents

Therapeutically active compounds and methods of use

Info

Publication number
IL243833A0
IL243833A0 IL243833A IL24383316A IL243833A0 IL 243833 A0 IL243833 A0 IL 243833A0 IL 243833 A IL243833 A IL 243833A IL 24383316 A IL24383316 A IL 24383316A IL 243833 A0 IL243833 A0 IL 243833A0
Authority
IL
Israel
Prior art keywords
methods
active compounds
therapeutically active
therapeutically
compounds
Prior art date
Application number
IL243833A
Other languages
English (en)
Hebrew (he)
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2013/081170 external-priority patent/WO2015018060A1/en
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of IL243833A0 publication Critical patent/IL243833A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
IL243833A 2013-08-02 2016-01-28 Therapeutically active compounds and methods of use IL243833A0 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361861884P 2013-08-02 2013-08-02
PCT/CN2013/081170 WO2015018060A1 (en) 2013-08-09 2013-08-09 Crystalline forms of therapeutically active compounds and use thereof
US201461939098P 2014-02-12 2014-02-12
US201461975448P 2014-04-04 2014-04-04
US201462011948P 2014-06-13 2014-06-13
PCT/US2014/049469 WO2015017821A2 (en) 2013-08-02 2014-08-01 Therapeutically active compounds and their methods of use

Publications (1)

Publication Number Publication Date
IL243833A0 true IL243833A0 (en) 2016-04-21

Family

ID=52432592

Family Applications (2)

Application Number Title Priority Date Filing Date
IL243833A IL243833A0 (en) 2013-08-02 2016-01-28 Therapeutically active compounds and methods of use
IL270347A IL270347B (en) 2013-08-02 2019-10-31 Therapeutically active compounds and methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL270347A IL270347B (en) 2013-08-02 2019-10-31 Therapeutically active compounds and methods of use

Country Status (21)

Country Link
US (5) US9738625B2 (enExample)
EP (3) EP3932408A1 (enExample)
JP (3) JP6742905B2 (enExample)
CN (3) CN110386922A (enExample)
AU (2) AU2014295938B2 (enExample)
BR (1) BR112016002287A2 (enExample)
CA (1) CA2919382A1 (enExample)
CL (2) CL2016000263A1 (enExample)
EA (1) EA030428B1 (enExample)
ES (1) ES2886211T3 (enExample)
IL (2) IL243833A0 (enExample)
MX (2) MX389250B (enExample)
MY (1) MY177994A (enExample)
NI (1) NI201600022A (enExample)
PE (1) PE20160840A1 (enExample)
PH (1) PH12016500164B1 (enExample)
SA (1) SA516370523B1 (enExample)
SG (2) SG11201600479WA (enExample)
TW (2) TWI666208B (enExample)
UA (1) UA121021C2 (enExample)
WO (1) WO2015017821A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EA030428B1 (ru) * 2013-08-02 2018-08-31 Аджиос Фармасьютикалз, Инк. Терапевтически активные соединения и способы их применения
US9694013B2 (en) 2014-09-29 2017-07-04 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN107531675A (zh) 2015-02-04 2018-01-02 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
CN107922354B (zh) * 2015-05-07 2021-05-25 苏州韬略生物科技有限公司 作为idh2抑制剂的杂环化合物
ES2881695T3 (es) * 2015-07-30 2021-11-30 Chia Tai Tianqing Pharmaceutical Group Co Ltd Derivado de 1,3,5-triazina y método de uso del mismo
EP3331866B1 (en) 2015-08-05 2023-07-26 Les Laboratoires Servier Methods of preparing a 6-heteroaryl-1,3,5-triazine-2,4-diol and a 6-heteroaryl-1,3,5-triazine-2,4-diamine
EP3362070B1 (en) * 2015-10-15 2021-01-27 Celgene Corporation Combination of a mutant isocitrate dehydrogenase 2 inhibitor with azacitidine and its use for treating acute myelogenous leukemia
EP3362057A1 (en) 2015-10-15 2018-08-22 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
WO2017069878A1 (en) * 2015-10-21 2017-04-27 NeuForm Pharmaceuticals, Inc. Deuterated compounds for treating hematologic malignancies, and compositions and methods thereof
EP3383400B1 (en) * 2015-12-04 2022-01-05 Les Laboratoires Servier Methods of treatment of malignancies
WO2017140758A1 (en) 2016-02-19 2017-08-24 Debiopharm International S.A. Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers
MX390396B (es) 2016-02-26 2025-03-20 Celgene Corp Enasidenib para usarse en leucemia mieloide aguda recidivante o refractaria.
US20180042930A1 (en) 2016-08-03 2018-02-15 Celgene Corporation Methods of treatment of malignancies
JP7093764B2 (ja) * 2016-08-03 2022-06-30 セルジーン コーポレイション 骨髄異形成症候群の治療方法
BR112019004356A2 (pt) * 2016-09-07 2019-05-28 Celgene Corporation composições de comprimido
CN113549056A (zh) * 2017-01-22 2021-10-26 正大天晴药业集团股份有限公司 1,3,5-三嗪衍生物的盐及其晶体、它们的制备方法、药物组合物和用途
EP3618828B1 (en) * 2017-05-05 2023-11-01 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
PL3644999T3 (pl) 2017-06-30 2023-05-08 Celgene Corporation Kompozycje i sposoby zastosowania 2-(4-chlorofenylo)-n-((2-(2,6-dioksopiperydyn-3-ylo)-1-oksoizoindolin-5-ylo)metylo)-2,2-difluoroacetamidu
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
WO2020092906A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
US12215094B2 (en) * 2018-11-02 2025-02-04 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
CN115243690A (zh) 2019-11-14 2022-10-25 新基公司 用于治疗癌症的儿科制剂
CN114773320A (zh) * 2022-05-29 2022-07-22 重庆医科大学 1,3,5-三嗪化合物及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390529A (en) 1942-02-03 1945-12-11 Ernst A H Friedheim Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds
JPS58186682A (ja) 1982-04-27 1983-10-31 日本化薬株式会社 セルロ−ス又はセルロ−ス含有繊維材料の染色法
DE3512630A1 (de) 1985-04-06 1986-10-23 Hoechst Ag, 6230 Frankfurt Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern
EP0466647B1 (de) 1990-07-12 1995-11-29 Ciba-Geigy Ag Verfahren zur photochemischen und thermischen Stabilisierung von Polyamid-Fasermaterialien
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
US6274620B1 (en) 1999-06-07 2001-08-14 Biochem Pharma Inc. Thiophene integrin inhibitors
US7291616B2 (en) * 2001-10-31 2007-11-06 Cell Therapeutics, Inc. Aryl triazines as LPAAT-β inhibitors and uses thereof
SI2256108T1 (sl) 2002-07-18 2016-05-31 Janssen Pharmaceutica N.V. Substituirani triazinski kinazni inhibitorji
DK2152676T3 (da) 2007-04-30 2013-07-01 Prometic Biosciences Inc Triazinderivater, sammensætninger, der indeholder sådanne derivater, og fremgangsmåde til behandling af cancer og autoimmunsygdomme ved anvendelse af sådanne derivater
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
CN102573485B (zh) * 2009-06-08 2014-11-26 加利福尼亚资本权益有限责任公司 三嗪衍生物及其治疗应用
CA2987503C (en) * 2009-07-07 2019-02-26 Mei Pharma, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
AU2013207289B2 (en) * 2012-01-06 2017-09-21 Les Laboratoires Servier Therapeutically active compounds and their methods of use
WO2013133367A1 (ja) 2012-03-09 2013-09-12 カルナバイオサイエンス株式会社 新規トリアジン誘導体
EP3019490B1 (en) 2013-07-11 2020-06-03 Agios Pharmaceuticals, Inc. N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
EA030428B1 (ru) * 2013-08-02 2018-08-31 Аджиос Фармасьютикалз, Инк. Терапевтически активные соединения и способы их применения
US9694013B2 (en) 2014-09-29 2017-07-04 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN107531675A (zh) 2015-02-04 2018-01-02 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法

Also Published As

Publication number Publication date
ES2886211T3 (es) 2021-12-16
AU2014295938B2 (en) 2018-07-19
TW201932455A (zh) 2019-08-16
EA030428B1 (ru) 2018-08-31
SA516370523B1 (ar) 2019-01-10
CN110372670A (zh) 2019-10-25
AU2014295938A1 (en) 2016-02-18
CA2919382A1 (en) 2015-02-05
CL2016000263A1 (es) 2016-08-19
MY177994A (en) 2020-09-28
WO2015017821A2 (en) 2015-02-05
EP3932408A1 (en) 2022-01-05
NI201600022A (es) 2016-03-16
JP2016527279A (ja) 2016-09-08
NZ716226A (en) 2021-08-27
JP2019142930A (ja) 2019-08-29
EA201690322A1 (ru) 2016-07-29
IL270347B (en) 2021-08-31
EP3566706A1 (en) 2019-11-13
UA121021C2 (uk) 2020-03-25
MX389250B (es) 2025-03-20
MX2016001361A (es) 2016-06-14
CN105916507A (zh) 2016-08-31
AU2018247242A1 (en) 2018-11-01
MX2020011397A (es) 2022-08-05
US20210155603A1 (en) 2021-05-27
JP6742905B2 (ja) 2020-08-19
JP2021176893A (ja) 2021-11-11
US20160194305A1 (en) 2016-07-07
PH12016500164A1 (en) 2016-04-25
WO2015017821A3 (en) 2015-04-09
CL2017002240A1 (es) 2018-04-20
SG11201600479WA (en) 2016-02-26
EP3566706B1 (en) 2021-07-14
US10093654B2 (en) 2018-10-09
CN110372670B (zh) 2023-04-07
BR112016002287A2 (pt) 2017-08-01
PE20160840A1 (es) 2016-09-22
TWI666208B (zh) 2019-07-21
MX394658B (es) 2025-03-24
EP3027193A2 (en) 2016-06-08
TW201524971A (zh) 2015-07-01
US20240132474A1 (en) 2024-04-25
EP3027193A4 (en) 2017-04-26
SG10201709187TA (en) 2017-12-28
CN110386922A (zh) 2019-10-29
US20180370951A1 (en) 2018-12-27
TWI701242B (zh) 2020-08-11
US10730854B2 (en) 2020-08-04
AU2018247242B2 (en) 2020-03-12
PH12016500164B1 (en) 2023-11-08
US9738625B2 (en) 2017-08-22
US20170305885A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
IL270347B (en) Therapeutically active compounds and methods of use
ZA202100373B (en) Therapeutically active compounds and their methods of use
ZA201600667B (en) Therapeutically active compounds and their methods of use
IL276289B (en) Medicinal uses of empagliflozin
ZA201405163B (en) Therapeutically active compounds and their methods of use
EP2804850A4 (en) THERAPEUTIC ACTIVE SUBSTANCES AND METHOD FOR THEIR USE
TWI560180B (en) Substituted benzamides and methods of use thereof
GB201320729D0 (en) Therapeutic compounds and their use
IL251246A0 (en) Therapeutically active compounds and methods of use
IL253796A0 (en) Therapeutically active compounds and methods of use
IL241101B (en) Medicinal uses of empagliflozin
IL241102A0 (en) Medicinal uses of empagliflozin
PT3019477T (pt) Compostos heterocíclicos e métodos para a sua utilização
GB201311361D0 (en) Compounds and their therapeutic use
SI3598971T1 (sl) Odmerne oblike in terapevtske uporabe L-4-klorokinurenina
GB201308736D0 (en) Compounds and their therapeutic use
GB201317804D0 (en) Therapeutic compounds and their use
GB201316173D0 (en) Compounds and their therapeutic use
GB201307677D0 (en) Compounds and their therapeutic use